A Fresh Route to Seed Capital in Life Sciences
Raising early-stage cash for a biotech spin-out can feel like navigating a maze. You’ve got groundbreaking science and a vision that could reshape patient care, but where do you find patient investors who appreciate the long development cycles? Enter SEIS and EIS, two government-backed schemes designed to sweeten the deal for angels and high-net-worth individuals—with hefty tax reliefs if you tick the right boxes.
This practical guide cuts through the jargon. You’ll learn the nuts and bolts of SEIS & EIS, why traditional VC firms such as AdBio Partners might not suit every biotech founder, and how a commission-free marketplace can transform your fundraising journey. Let’s dive into life sciences startup funding—no fluff, just actionable steps—and see how a tailored platform can streamline the entire process. Revolutionising life sciences startup funding in the UK
Understanding SEIS and EIS Schemes in the UK
Venture builders and angel networks often talk in acronyms. SEIS (Seed Enterprise Investment Scheme) and EIS (Enterprise Investment Scheme) sound complicated, but their core aim is simple: reduce investor risk by offering tax relief. The Government wants to back tomorrow’s cures by making it more attractive for individuals to write a cheque today.
What is SEIS?
SEIS targets very early stages. If your company is less than two years old and has fewer than 25 staff, you qualify for:
– 50% income tax relief on investments up to £100,000 per investor
– Capital gains exemption on SEIS shares held for over three years
– Loss relief if things go south
It’s a potent cocktail of incentives for anyone betting on high-risk innovations in biotech or med-tech.
What is EIS?
Once you clear SEIS thresholds, EIS takes over. Key benefits include:
– 30% income tax relief on investments up to £1 million per investor
– Roll-over relief on capital gains
– Loss relief to offset against income tax
EIS is ideal for companies in their next growth phase—scaling clinical trials or building a regulatory dossier.
Key Tax Reliefs and Eligibility Criteria
To qualify, you must meet rules on share capital, full-time employees and permitted trade activities. Your articles of association need to reflect genuine risk capital. Keep documentation tight: board minutes, share registers and accounts must all align with HMRC’s requirements.
Traditional VC Investment vs Commission-Free Marketplaces
Many biotech founders look first to established VCs. AdBio Partners, for example, invests directly in and nurtures early-stage life sciences ventures across Europe. They have deep scientific networks and can lead syndicates through Series A, B and beyond.
AdBio Partners’ Venture Capital Model
AdBio Partners mentors spin-outs from leading research centres, pooling funds into a high-conviction portfolio. Their experts guide scientific founders on business strategy and clinical planning. It’s a hands-on approach that suits companies seeking significant cheque sizes and tactical support.
Limitations of Traditional VC for Early-Stage Biotech
- Lengthy due diligence can stretch months
- High minimum investment thresholds deter smaller angels
- Standard deal terms may include board seats and liquidation preferences
- Commission or carried interest structures mean founders give up a slice of future returns
While invaluable to some, this model can lock out founders who need rapid access to a diverse pool of SEIS/EIS-savvy investors.
How Oriel IPO’s Platform Differs
Oriel IPO offers a commission-free, subscription-based marketplace that vets startups for SEIS/EIS eligibility. You retain more of your equity, and every investor on the platform understands tax-efficient funding. There’s no middleman taking a cut of your raise. Instead, you pay a clear subscription fee to showcase your opportunity and tap into a curated network of angels and advisers.
Step-by-Step Guide to Securing SEIS & EIS Funding
You’ve weighed the options. Now let’s break down the practical steps to close your first round under SEIS or EIS.
1. Preparing Your Startup
Get your house in order before you pitch. You’ll need:
– A succinct pitch deck outlining your science, market and milestones
– Articles of association that confirm share capital specifics
– Historical accounts (even if minimal) that comply with Companies House
– A plan for how you’ll use the cash to unlock the next technical or regulatory milestone
This groundwork smooths the path for investor due diligence.
2. Navigating Compliance and Documentation
Every SEIS/EIS claim requires precise paperwork. HMRC wants to see:
– Qualified share identification (Form SEIS1/EIS1)
– HMRC advance assurance letters
– Evidence of how funds are deployed (reports, invoices, payroll details)
Missing or misfiled forms means delayed relief for investors—and a harder sell.
3. Pitching to Investors on Oriel IPO
Once compliant, list your opportunity on a platform built for life sciences startup funding. You’ll benefit from:
– A community of tax-aware angels focused on biotech
– Educational webinars on optimising claims and structuring rounds
– Transparent subscription costs, no hidden commission fees
Many founders see an uptick in investor interest within weeks of going live. Secure life sciences startup funding without commission fees
Pros and Cons: Choosing the Right Path
Every funding route has merits. Here’s a quick comparison:
Traditional VC (e.g. AdBio Partners)
– Pros: Large cheques, strategic guidance, established reputation
– Cons: Longer timelines, complex term sheets, carried interest
Commission-Free Marketplaces (Oriel IPO)
– Pros: Faster listings, no commission on raises, tax-focused investor pool
– Cons: Subscription fees, less bespoke mentorship
Match your needs: if you need rapid seed funding and want to maintain control, a marketplace often wins. For multi-million Series A or specialist advice, a VC might be better.
Testimonials from UK Biotech Founders
“Partnering with Oriel IPO was a game-changer for us. We had our SEIS advance assurance within weeks, and the investor community got our vision immediately. The zero commission model meant we kept every penny raised.”
— Dr Sarah Mitchell, Founder, Novacure Therapeutics
“Oriel IPO’s curated platform connected us with angels who really understood biotech. Their educational guides on SEIS/EIS saved us hours of head-scratching. Highly recommended if you want streamlined, tax-efficient funding.”
— James Clarke, CEO, BioGeneX
“I appreciated how Oriel IPO demystified compliance. Their team walked us through every document, ensuring investors got their relief promptly. We closed our round faster than we expected.”
— Priya Singh, Co-founder, NeuroGene Labs
Next Steps and Resources
Securing SEIS & EIS funding doesn’t have to be a bureaucratic marathon. With clear documentation, the right pitch and a commission-free marketplace, you can accelerate your life sciences startup’s journey from lab bench to clinic. Remember to:
- Engage professional advisers (solicitors, accountants) early
- Seek HMRC advance assurance to reassure investors
- Utilise educational webinars and templates offered by platforms
Your research pipeline deserves funding that matches its potential. Explore life sciences startup funding opportunities today
With a strategic approach and the right platform, you’ll turn that lab-grown idea into tomorrow’s medical breakthrough.
